258. Deputy Tony McLoughlin asked the Minister for Health his views on the fact that in 2018 it was announced that Pembrolizumab would be licensed in April 2018 for NSCLC patients however his Department and the HSE attached a narrow window of eligibility as it is a requirement that the tumour has a PD-L1 expression of over 50%; if this requirement can be reduced to bring it in line with similar drugs such as Nivolumab; and if he will make a statement on the matter. [17350/18]

Summary

258. Deputy Tony McLoughlin asked the Minister for Health his views on the fact that in 2018 it was announced that Pembrolizumab would be licensed in April 2018 for NSCLC patients however his Department and the HSE attached a narrow window of eligibility as it is a requirement that the tumour has a PD-L1 expression of over 50%; if this requirement can be reduced to bring it in line with similar drugs such as Nivolumab; and if he will make a statement on the matter. [17350/18]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Reimbursement

  xml · EN · 19 April 2018

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.